Home › Medical › Cannabis and Chronic Pain
⚐ Flag an error How this page was made
Also known as: cannabis for pain management · THC for chronic pain · CBD and pain relief

Cannabis and Chronic Pain

Evidence summary of cannabis for chronic pain: modest benefit for some, real risks, and how it compares to standard care.

Automated fact-check pass
16 cited sources
Published
Last reviewed
How this page was made

This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.

↯ The honest take

Cannabis produces real but modest pain relief in some people—roughly one in three gets meaningful improvement versus one in five on placebo. It works best for nerve pain. But dispensary marketing vastly overstates the effect, and long-term data are sparse. For most chronic pain, evidence-backed first-line treatments (exercise, physical therapy, specific antidepressants) should come first. Cannabis is worth considering when standard options fail or cause side effects.

Not Medical Advice

This article is educational, not medical advice. Chronic pain has many causes, and cannabis interacts with medications—especially opioids, benzodiazepines, blood thinners, anticonvulsants, and some antidepressants. Always speak with a clinician who knows your case before starting, stopping, or substituting any treatment.

If you are pregnant, have a personal or family history of psychosis, or have serious cardiovascular disease, the risk profile changes substantially. Do not use this article to replace clinical judgment.

Plain-Language Summary

Dozens of randomized controlled trials and systematic reviews show that cannabis and cannabis-based medicines produce a small-to-moderate reduction in chronic pain for some people. The 2017 National Academies report rated the evidence for chronic pain in adults as 'substantial,' but later reviews have refined that: the effect is real but modest, and the quality of evidence varies widely by pain type [1] Strong evidence.

A practical benchmark from trial data: about one in three patients achieves a clinically meaningful (≥30%) reduction in pain compared to about one in five on placebo [2] Strong evidence. That's a clear signal above background, but it contrasts sharply with dispensary marketing claims of profound relief.

The body of evidence is strongest for nerve-related pain (neuropathic pain) and weaker for most other conditions. Efficacy is modest and individual responses are highly variable.

What Probably Works: Strong Evidence

Neuropathic Pain

This is the strongest indication. Multiple RCTs of inhaled cannabis, oral THC, and the THC/CBD spray nabiximols (Sativex) consistently show modest reductions in pain from nerve injury—including diabetic neuropathy, HIV-associated neuropathy, post-surgical nerve pain, and multiple sclerosis-related neuropathic pain [2][4] Strong evidence. Nabiximols is approved in the UK, Canada, Germany, and several other countries specifically for MS-related neuropathic pain and spasticity [5] Strong evidence.

Multiple Sclerosis–Related Spasticity and Associated Pain

Nabiximols (Sativex) has the clearest regulatory evidence and approved labeling for MS spasticity [5] Strong evidence. This is the best-supported single indication.

Cancer Pain (as Add-On Therapy)

Evidence is weaker but consistent: cannabinoids added to opioid regimens may reduce pain intensity or allow lower opioid doses in some patients with cancer pain [3] Weak / limited. Not a first-line treatment, but a reasonable second-line adjunct when standard opioid doses are poorly tolerated or ineffective.

What Might Work: Limited or Mixed Evidence

Fibromyalgia

Small RCTs of nabilone and inhaled cannabis show some benefit on pain and sleep quality, but studies are few, short (typically 4–12 weeks), and involve small samples [6] Weak / limited. This indication lacks the robust evidence base of neuropathic pain.

Chronic Headache and Migraine

Patient surveys and observational case series report relief from headache and migraine with cannabis use, but well-designed RCTs are sparse [7] Weak / limited. Marketing and anecdote far exceed controlled data. See Cannabis and Neuropathic Pain for discussion of trigeminal neuropathic pain specifically.

Opioid-Sparing Effects

Retroactive observational studies from legal-cannabis states report some patients reduce opioid doses [8] Disputed. However, early ecological studies suggesting cannabis legalization reduced opioid overdose deaths at the population level have not been borne out in longer follow-up analyses [9] Disputed. Individual opioid reduction is plausible in some patients; population-level benefits are unproven.

Isolated CBD for Chronic Pain

Despite heavy marketing, high-quality RCTs of isolated CBD (without THC) for chronic pain are limited and mostly negative or inconclusive [10] Weak / limited. Most positive cannabinoid trials involve THC or THC+CBD combinations, not CBD alone.

What Doesn't Work (or Is Marketing)

Indica vs. Sativa for Pain Control

The claim that "indica strains are better for pain" lacks scientific basis. The indica/sativa classification does not reliably predict chemical content (THC, CBD, terpene levels) or clinical effects [11] Strong evidence. This is a folk category, not a guide to pharmacology.

Specific Terpene Thresholds

Marketing claims (e.g., "myrcene above 0.5% is sedating" or "pinene enhances focus") have no supporting controlled human data No data. Terpenes are present in much higher concentrations in food and beverages with no psychoactive effect.

CBD Topical Products for Deep Joint or Nerve Pain

Skin penetration of CBD is limited, and clinical evidence for topical CBD treating arthritis, deep neuropathic pain, or nerve injury is thin Weak / limited. Topical CBD may help superficial musculoskeletal soreness, but it does not reach joints or deep nerve tissue in therapeutic concentrations.

Disease Reversal

Cannabis modulates pain sensation. It does not halt or reverse the underlying disease—it does not slow arthritis progression, regenerate damaged nerves, or treat cancer. It is symptomatic only.

What We Don't Know

Optimal Dose and THC:CBD Ratio

Randomized trials use widely varying products, doses, and cannabinoid ratios with no consensus on what works best for any specific pain condition No data. No standard dosing regimen exists.

Long-Term Efficacy and Tolerance

Most RCTs last weeks to a few months. Whether chronic daily cannabis use maintains pain relief over months or years, or whether tolerance develops, is unclear [3] Weak / limited.

Whole-Plant vs. Isolated Cannabinoids

The "entourage effect" hypothesis—that minor cannabinoids and terpenes enhance THC and CBD effects—is plausible but has weak direct clinical evidence Weak / limited.

Predictor of Response

No reliable biomarker, genetic profile, or patient characteristic predicts who will be among the ~30% of responders and who will not benefit No data.

Minor Cannabinoids (CBG, CBN, THCV)

These are aggressively marketed for pain relief, but controlled human trials are almost nonexistent No data.

Comparison With Standard Treatments

Efficacy

Effect sizes for cannabinoids in chronic pain RCTs are roughly comparable to—or somewhat smaller than—gabapentinoids (gabapentin, pregabalin) and tricyclic antidepressants (e.g., amitriptyline) for neuropathic pain [2][4] Strong evidence. Cannabinoids are generally weaker than opioids for acute and cancer pain but carry a radically different safety profile: cannabis has essentially zero acute overdose fatality risk, while opioids cause tens of thousands of overdose deaths annually in the United States Strong evidence.

Non-Neuropathic Chronic Pain (Low Back Pain, Osteoarthritis)

For these conditions, exercise therapy, physical therapy, and serotonin-norepinephrine reuptake inhibitors (SNRIs) such as duloxetine generally have equal or stronger evidence and should typically be attempted first [12] Strong evidence.

Reasonable Clinical Role

Cannabis is a legitimate option to consider when first-line, evidence-backed treatments have failed or caused intolerable side effects—particularly for neuropathic pain. It is not a replacement for standard care as an initial approach.

Risks and Serious Side Effects

Common, Usually Mild

Dizziness, dry mouth, sedation, cognitive slowing, anxiety, and increased appetite occur frequently [2][3] Strong evidence. These side effects cause many trial participants to discontinue treatment.

Psychiatric Risk

THC can precipitate or worsen psychosis in vulnerable individuals; risk increases with high-THC products and frequent use, especially in younger users and those with genetic or personal psychiatric history [13] Strong evidence. This is not rare—it is dose and frequency dependent.

Cannabis Use Disorder and Dependence

Roughly 9–10% of adult cannabis users develop cannabis use disorder; rates are higher among daily users and younger-age initiates [14] Strong evidence. Withdrawal symptoms (irritability, sleep disruption, anxiety) occur in dependent users upon cessation.

Cardiovascular Effects

Acute THC use raises heart rate and may increase the risk of cardiovascular events in older patients or those with pre-existing cardiac disease [15] Weak / limited. This risk is not fully quantified but should not be ignored in at-risk populations.

Driving and Cognitive Impairment

THC impairs reaction time, coordination, and judgment in a dose-dependent manner Strong evidence. Driving while impaired increases crash risk.

Cannabinoid Hyperemesis Syndrome (CHS)

This paradoxical syndrome of severe, cyclical vomiting occurs in some chronic heavy users, typically those using high-THC products daily Strong evidence. It is distressing and can lead to dehydration and electrolyte imbalance.

Drug Interactions

CBD inhibits several hepatic cytochrome P450 enzymes (CYP3A4, CYP2C9, CYP2C19) and can raise blood levels of many medications, including some anticonvulsants, blood thinners, and other pain medications [16] Strong evidence. See Cannabis and Polypharmacy Risks for detailed guidance.

Respiratory Risk (If Smoked)

Smoked cannabis causes acute respiratory irritation; long-term effects on the lungs are less clear than for tobacco but respiratory symptoms are common Strong evidence. Vaporization and oral products avoid combustion byproducts.

Special Populations

Pregnancy

Cannabis use during pregnancy has been associated with lower birth weight and developmental concerns in some observational studies Weak / limited. Risk is not fully characterized, but use during pregnancy is not recommended Strong evidence. See Cannabis and Pregnancy: Risks and Evidence.

Older Adults

Older patients may be more sensitive to THC, have more drug interactions (especially with opioids, benzodiazepines, and anticoagulants), and face higher cardiovascular risk Weak / limited. Dose escalation should be cautious.

History of Substance Use Disorder

Individuals with a personal or family history of addiction have elevated risk for cannabis use disorder Weak / limited. This is not an absolute contraindication but requires informed consent and close monitoring.

Bottom Line

Cannabis produces real but modest pain relief in some patients, most reliably for neuropathic pain. Roughly one in three patients experiences a clinically meaningful reduction in pain—a genuine signal, but far below what marketing suggests. The quality of evidence is strongest for neuropathic pain and weakest for other conditions like fibromyalgia or migraine.

For most chronic pain conditions, first-line treatments (exercise, physical therapy, standard medications) have equal or stronger evidence and should be prioritized. Cannabis is a reasonable second-line or adjunctive option when standard care fails or causes unacceptable side effects.

Risks are real: psychiatric effects (especially with high-THC products), dependence (~10% of regular users), drug interactions, and driving impairment are all documented. Individual responses vary dramatically, and long-term efficacy remains unknown.

If considering cannabis for chronic pain, work with a clinician who understands both cannabis pharmacology and your full medical and medication history.

Sources

  1. Government National Academies of Sciences, Engineering, and Medicine. (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press.
  2. Peer-reviewed Whiting PF, Wolff RF, Deshpande S, et al. (2015). Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA, 313(24), 2456–2473.
  3. Peer-reviewed Fisher E, Moore RA, Fogarty AE, et al. (2021). Cannabinoids, cannabis, and cannabis-based medicines for pain management: a systematic review of randomised controlled trials. Pain, 162(Suppl 1), S45–S66.
  4. Peer-reviewed Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. (2018). Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews, 3, CD012182.
  5. Government European Medicines Agency & UK Medicines and Healthcare products Regulatory Agency. (2018–2024). Nabiximols (Sativex) Summary of Product Characteristics, approved for MS spasticity in UK, Canada, Germany, Spain, and other jurisdictions.
  6. Peer-reviewed Walitt B, Klose P, Fitzcharles MA, Phillips T, Häuser W. (2016). Cannabinoids for fibromyalgia. Cochrane Database of Systematic Reviews, 7, CD011694.
  7. Peer-reviewed Baron EP. (2018). Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science. Headache, 58(7), 1139–1186.
  8. Peer-reviewed Boehnke KF, Litinas E, Clauw DJ. (2016). Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain. Journal of Pain, 17(6), 739–744.
  9. Peer-reviewed Shover CL, Davis CS, Gordon SC, Humphreys K. (2019). Association between medical cannabis laws and opioid overdose mortality has reversed over time. Proceedings of the National Academy of Sciences USA, 116(26), 12624–12626.
  10. Peer-reviewed Gulbransen G, Xu W, Arroll B. (2020). Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand. BJGP Open, 4(1), e101010.
  11. Peer-reviewed Piomelli D, Russo EB. (2016). The Cannabis sativa Versus Cannabis indica Debate: An Interview with Ethan Russo, MD. Cannabis and Cannabinoid Research, 1(1), 44–46.
  12. Government Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. (2022). CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. Morbidity and Mortality Weekly Report. Recommendations and Reports, 71(3), 1–95.
  13. Peer-reviewed Di Forti M, Quattrone D, Freeman TP, et al. (2019). The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry, 6(5), 427–436.
  14. Peer-reviewed Hasin DS, Saha TD, Kerridge BT, et al. (2015). Prevalence of Marijuana Use Disorders in the United States Between 2001–2002 and 2012–2013. JAMA Psychiatry, 72(12), 1235–1242.
  15. Peer-reviewed Page RL, Allen LA, Kloner RA, et al. (2020). Medical Marijuana, Recreational Cannabis, and Cardiovascular Health: A Scientific Statement From the American Heart Association. Circulation, 142(10), e131–e152.
  16. Peer-reviewed Brown JD, Winterstein AG. (2019). Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. Journal of Clinical Medicine, 8(7), 989.

How this page was made

Generation history

Oct 30, 2026
Revision
Oct 29, 2026
Fact-check pass — raised 10 flags
May 17, 2026
Self-review — raised 3 flags
May 11, 2026
Fact-check pass — raised 4 flags
May 11, 2026
Initial draft

Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.